The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Andrew Hollman Meyer net worth and biography

Andrew Meyer Biography and Net Worth

Chief Business Officer of Janux Therapeutics

Andy has more than 10 years of experience in biotechnology as an investment banker at Evercore and BofA Securities, Inc., where he advised biotechnology and life sciences companies on capital raising and strategic matters. At these firms, he successfully executed more than $20 billion in mergers and acquisitions and over 40 capital markets transactions, including initial public offerings (IPOs), follow-ons, convertible notes, and private placements. Andy joins Janux from Evercore, where he served as a Managing Director in the firm’s corporate advisory business with a focus on biotechnology. Prior to joining Evercore, he spent five years at BofA Securities, Inc. (previously Bank of America Merrill Lynch) in their healthcare investment banking practice.

Andy received a BSBA in finance from Georgetown University and an MBA from the USC Marshall School of Business.

What is Andrew Hollman Meyer's net worth?: The estimated net worth of Andrew Hollman Meyer is at least $3.31 million as of September 27th, 2024. Mr. Meyer owns 67,592 shares of Janux Therapeutics stock worth more than $3,309,304 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Meyer may own. Learn More about Andrew Hollman Meyer's net worth.
How do I contact Andrew Hollman Meyer?: The corporate mailing address for Mr. Meyer and other Janux Therapeutics executives is , , . Janux Therapeutics can also be reached via phone at 858-751-4493 and via email at [email protected]. Learn More on Andrew Hollman Meyer's contact information.
Has Andrew Hollman Meyer been buying or selling shares of Janux Therapeutics?: Andrew Hollman Meyer has not been actively trading shares of Janux Therapeutics during the last quarter. Most recently, Andrew Hollman Meyer sold 50,000 shares of the business's stock in a transaction on Friday, September 27th. The shares were sold at an average price of $45.96, for a transaction totalling $2,298,000.00. Following the completion of the sale, the insider now directly owns 67,592 shares of the company's stock, valued at $3,106,528.32. Learn More on Andrew Hollman Meyer's trading history.
Who are Janux Therapeutics' active insiders?: Janux Therapeutics' insider roster includes David Campbell (Founder, President & CEO), and Andrew Meyer (Chief Business Officer). Learn More on Janux Therapeutics' active insiders.
Are insiders buying or selling shares of Janux Therapeutics?: During the last year, Janux Therapeutics insiders bought shares 1 times. They purchased a total of 1,200,000 shares worth more than $53,700,000.00. During the last year, insiders at the sold shares 12 times. They sold a total of 3,420,610 shares worth more than $183,538,665.79. The most recent insider tranaction occured on October, 28th when CEO David Alan Campbell sold 25,000 shares worth more than $1,338,500.00. Insiders at Janux Therapeutics own 29.4% of the company. Learn More about insider trades at Janux Therapeutics.
Information on this page was last updated on 10/28/2024.

Andrew Hollman Meyer Insider Trading History at Janux Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/27/2024	Sell	50,000	$45.96	$2,298,000.00	67,592

Andrew Hollman Meyer Buying and Selling Activity at Janux Therapeutics

Janux Therapeutics Company Overview

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Today's Range

Now: $48.96

$47.61

$49.33

50 Day Range

MA: $50.06

$43.45

$55.95

2 Week Range

Now: $48.96

$7.79

$65.60

Volume

391,493 shs

Average Volume

689,766 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.52

Financial Prophecy

From Porter & Company | Ad